Table 4.
Baseline clinical characteristics for human cohort receiving pembrolizumab.
| Patient Race | ||
|---|---|---|
| White | 24 | 51.72% |
| Black | 2 | 4.76% |
| Hispanic | 15 | 35.71% |
| Asian | 1 | 2.38% |
| Total | 42 | 100% |
| Patient Sex | ||
| Male | 22 | 52.38% |
| Female | 20 | 47.62% |
| Total | 42 | 100% |
| Body Mass Index | ||
| Median | 25.27 | |
| Mean | 25.89 | |
| Age (years) | ||
| Median | 71 | |
| Mean | 70.69 | |
| Smoking History | ||
| Never | 3 | 7.14% |
| <15 pack years | 7 | 16.67% |
| 15-30 pack years | 13 | 30.95% |
| >30 pack years | 19 | 45.24% |
| Total | 42 | 100% |
| Pre-Treatment ECOG PS | ||
| 0 | 6 | 14.29% |
| 1 | 32 | 76.19% |
| 2 | 3 | 7.14% |
| 3 | 1 | 2.38% |
| Total | 42 | 100% |
| Pathology | ||
| Adenocarcinoma | 34 | 80.95% |
| Squamous Cell Carcinoma | 6 | 14.29% |
| Adenosquamous | 1 | 2.38% |
| Bronchoalveolar | 0 | 0% |
| NSCLC, NOS | 1 | 2.38% |
| Total | 42 | 100% |
| Number of Prior Systemic Therapies1 | ||
| 0 | 17 | 40.48% |
| 1 | 20 | 47.62% |
| 2 | 4 | 9.52% |
| 3 | 1 | 2.38% |
| 4 | 0 | 0% |
| Total | 42 | 100% |
| Mean | 0.738 | |
| Median | 1 | |
| Relapsed or de novo Metastatic Disease | ||
| Metachronous | 12 | 28.57% |
| Synchronous | 30 | 71.43% |
| PD-L1 Expression Status | ||
| High (>50%) | 24 | 61.54% |
| Low (1-49%) | 10 | 25.64% |
| Negative (<1%) | 5 | 12.82% |
| Missing | 3 | |
| Targetable Mutation Status | ||
| KRAS | 2 | 6.90% |
| EGFR | 4 | 13.79% |
| ALK | 1 | 3.45% |
| MET | 2 | 6.90% |
| BRAF V600E | 1 | 3.45% |
| None | 19 | 65.52% |
| Missing | 13 | |
| Daily Steroid Use | ||
| Taking | 7 | 16.67% |
| Median Prednisone Equivalent Dose (mg) | 20 | |
| Blood Count Tests | Median | Mean |
| NLR | 5.16 | 6.46 |
| PLR | 220.97 | 248.30 |
| NMR | 9.39 | 12.71 |
| LMR | 2.01 | 2.30 |
| Primary Tumor Size (cc) | ||
| Median | 11.10 | |
| Mean | 62.30 | |
| Nodal Disease at Time of ImT | ||
| Yes | 31 | 73.81% |
| No | 11 | 26.19% |
| Anatomic M Stage | ||
| M1a | 14 | 33.33% |
| M1b | 5 | 11.90% |
| M1c | 23 | 54.76% |
| Overall Stage | ||
| IVA | 19 | 45.2% |
| IVB | 23 | 54.8% |
| Prognostic Nutritional Index | ||
| Median | 43.6 | |
| Mean | 44.27 | |
1 Excluding Avastin.